

## Electronic Supporting Information

### Development of a Conformational Histamine H<sub>3</sub> receptor Biosensor for the Synchronous Screening of Agonists and Inverse Agonists.

Hannes Schihada<sup>1,2</sup> \*, Xiaoyuan Ma<sup>3</sup>, Ulrike Zabel<sup>2</sup>, Henry F. Vischer<sup>3</sup>, Gunnar Schulte<sup>1</sup>, Rob Leurs<sup>3</sup>, Steffen Pockes<sup>4</sup>, Martin J. Lohse<sup>2,5,6</sup> \*

<sup>1</sup>: Section of Receptor Biology & Signaling, Dept. Physiology & Pharmacology, Karolinska Institutet, Stockholm 171 77, Sweden.

<sup>2</sup>: Institute of Pharmacology and Toxicology and Rudolf Virchow Center, University of Würzburg, Würzburg 97070, Germany

<sup>3</sup>: Amsterdam Institute for Molecules, Medicines and Systems, Division of Medicinal Chemistry, Faculty of Science, Vrije Universiteit Amsterdam, Amsterdam 1081 HV, The Netherlands.

<sup>4</sup>: Institute of Pharmacy, Faculty of Chemistry and Pharmacy, University of Regensburg, Regensburg 93053, Germany.

<sup>5</sup>: ISAR Bioscience, Planegg 82152, Germany

<sup>6</sup>: Max Delbrück Center for Molecular Medicine, Berlin 13125, Germany

Correspondence to: [hannes.schihada@ki.se](mailto:hannes.schihada@ki.se) and [m.lohse@mdc.de](mailto:m.lohse@mdc.de)

**Supplementary Table 1. Summary of H<sub>3</sub>R ligand affinities/potencies and efficacies assessed with different assays**

Compound	Affinity for wildtype H <sub>3</sub> R (binding assay; p <i>K</i> <sub>D/i</sub> ± s.d.)	Affinity for Δicl3 H <sub>3</sub> R <sup>Nluc/Halo(618)</sup> (binding assay; p <i>K</i> <sub>D/i</sub> ± s.d.)	Potency at Δicl3-H <sub>3</sub> R <sup>Nluc/Halo(618)</sup> (conformational assay; pEC <sub>50</sub> ± s.d.)	Relative E <sub>max</sub> at wildtype H <sub>3</sub> R (type of assay)	Relative E <sub>max</sub> at Δicl3- H <sub>3</sub> R <sup>Nluc/Halo(618)</sup> (normalized to histamine ± s.e.m.)
[ <sup>3</sup> H] NAMH	8.9 ± 0.1	8.7 ± 0.2	n.d.	1.0 of histamine <sup>4</sup> (CRE reporter gene)	n.d.
histamine	6.3 ± 0.2 <sup>1</sup>	7.4 ± 0.1	6.7 ± 0.0	1.0 of histamine <sup>4</sup> (CRE reporter gene)	1.00 ± 0.02 *
RAMH	8.4 ± 0.1 <sup>2</sup>	8.3 ± 0.0	n.d.	1.0 of histamine <sup>4</sup> (CRE reporter gene)	n.d.
SAMH	7.6 ± 0.1 <sup>2</sup>	7.3 ± 0.1	n.d.	1.0 of histamine <sup>4</sup> (CRE reporter gene)	n.d.
imetit	8.3 ± 0.4 <sup>1</sup>	9.1 ± 0.1	8.2 ± 0.1	1.0 of histamine <sup>4</sup> (CRE reporter gene)	0.61 ± 0.01 *
impentamine	8.3 ± 0.1 <sup>3</sup>	8.6 ± 0.0	7.9 ± 0.2	0.9 of NAMH <sup>3</sup>	0.19 ± 0.02
VUF5207	7.8 ± 0.2 <sup>3</sup>	7.4 ± 0.0	7.8 ± 0.7	0.7 of NAMH <sup>3</sup>	0.10 ± 0.01
VUF4904	7.9 ± 0.1 <sup>3</sup>	7.7 ± 0.1	6.3 ± 0.2	-0.1 of NAMH <sup>3</sup>	-0.25 ± 0.04
VUF4903	8.0 ± 0.0 <sup>3</sup>	8.1 ± 0.1	6.5 ± 0.1	-0.6 of NAMH <sup>3</sup>	-0.46 ± 0.02

Compound	Affinity for wildtype H <sub>3</sub> R (binding assay; pK <sub>D/i</sub> ± s.d.)	Affinity for Δicl3 H <sub>3</sub> R <sup>Nluc/Halo(618)</sup> (binding assay; pK <sub>D/i</sub> ± s.d.)	Potency at Δicl3-H <sub>3</sub> R <sup>Nluc/Halo(618)</sup> (conformational assay; pEC <sub>50</sub> ± s.d.)	Relative E <sub>max</sub> at wildtype H <sub>3</sub> R (type of assay)	Relative E <sub>max</sub> at Δicl3- H <sub>3</sub> R <sup>Nluc/Halo(618)</sup> (normalized to histamine ± s.e.m.)
UR-PI294	9.0 ± 0.1 <sup>5</sup>	8.7 ± 0.1	8.5 ± 0.5	0.4 of histamine <sup>5</sup> (GTPase assay)	0.07 ± 0.01
clobenpropit	9.6 ± 0.1 <sup>1</sup>	9.3 ± 0.1	7.4 ± 0.0	-0.8 of histamine <sup>4</sup> (CRE reporter gene)	-0.38 ± 0.01
thioperamide	7.3 ± 0.3 <sup>1</sup>	7.2 ± 0.1	7.1 ± 0.1	-0.8 of histamine <sup>4</sup> (CRE reporter gene)	-0.30 ± 0.01
pitolisant	8.6 ± 0.0 <sup>1</sup>	8.0 ± 0.1	7.2 ± 0.0	-0.4 of histamine (CRE reporter gene)	-0.48 ± 0.01 <sup>#</sup>
Z27743747	7.4 <sup>6</sup>	7.3 ± 0.1	6.5 ± 0.1	unknown	-0.65 ± 0.02 <sup>#</sup>
Z3303614736	6.8 <sup>6</sup>	6.7 ± 0.1	6.5 ± 0.1	unknow	-0.53 ± 0.02

Non-referenced values were assessed in the present study. n.d.: not determined.


Values are mean ± s.d. of at least three independent experiments.

\*/#: Statistically significant difference between E<sub>max</sub> of histamine and imetit (\*) and between pitolisant and Z27743747 (#) in the conformational BRET assay. Significance was assessed applying extra-sum-of-squares F test (p < 0.0001).

## References:


- (1) Mocking, T.A.M., Verweij, E.W.E., Vischer, H.F., and Leurs, R. (2018). Homogeneous, Real-Time NanoBRET Binding Assays for the Histamine H3 and H4 Receptors on Living Cells. *Mol Pharmacol* 94, 1371-1381.
- (2) Wulff, B.S., Hastrup, S., and Rimvall, K. (2002). Characteristics of recombinantly expressed rat and human histamine H3 receptors. *Eur J Pharmacol* 453, 33-41.
- (3) Wieland, K., Bongers, G., Yamamoto, Y., Hashimoto, T., Yamatodani, A., Menge, W.M., Timmerman, H., Lovenberg, T.W., and Leurs, R. (2001). Constitutive activity of histamine h(3) receptors stably expressed in SK-N-MC cells: display of agonism and inverse agonism by H(3) antagonists. *J Pharmacol Exp Ther* 299, 908-914.
- (4) Lim, H.D., van Rijn, R.M., Ling, P., Bakker, R.A., Thurmond, R.L., and Leurs, R. (2005). Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist. *J Pharmacol Exp Ther* 314, 1310-1321.
- (5) Igel, P., Schnell, D., Bernhardt, G., Seifert, R., and Buschauer, A. (2009). Tritium-labeled N(1)-[3-(1H-imidazol-4-yl)propyl]-N(2)-propionylguanidine ([<sup>3</sup>H]UR-PI294), a high-affinity histamine H(3) and H(4) receptor radioligand. *ChemMedChem* 4, 225-231.
- (6) Schaller, D., Hagenow, S., Stark, H., and Wolber, G. (2019). Ligand-guided homology modeling drives identification of novel histamine H3 receptor ligands. *PLoS One* 14, e0218820, <https://doi.org/10.1371/journal.pone.0218820>.

Supplementary Figure 1.




Competition binding of selected unlabelled H<sub>3</sub>R ligands with [<sup>3</sup>H]NAMH to cells stably expressing Δicl3-H<sub>3</sub>R<sub>NiucHalo(618)</sub>.

Supplementary Figure 2.




BRET signals and Z-factors of  $\Delta$ icl3-H<sub>3</sub>R<sub>3</sub><sup>Niuc/Halo(618)</sup> assessed in four independent 96-well plates using histamine (a, b) or pitolisant (c, d) as positive controls to determine the screening windows for H<sub>3</sub>R agonists and inverse agonists, respectively.

Supplementary Figure 3.



Concentration response curves of H<sub>3</sub>R inverse agonists assessed with  $\Delta$ icl3-H<sub>3</sub>R<sub>Nluc/Halo(618)</sub> and normalized to the maximum histamine response.

Supplementary Figure 4.



Comparison of assay sensitivity without H<sub>3</sub>R agonist pre-stimulation. **a)** Luminescence and BRET responses induced by Z27743747 and Z3303614736 in cells expressing H<sub>3</sub>R wildtype along with the split Nluc-based G<sub>11</sub> sensor or the conformational H<sub>3</sub>R sensor Δicl3-H<sub>3</sub>R<sub>Nluc/Halo(618)</sub>, respectively. Statistical differences were assessed by one-way ANOVA followed by Bonferroni multiple comparison against vehicle control (\*p < 0.05). **b)** Corresponding signal-to-noise (S/N) ratios of Z27743747 and Z3303614736 in the two assays. S/N ratio was calculated as described in the methods section.